ICU Medical, Inc. $ICUI Stock Sold by William Blair Investment Management LLC

William Blair Investment Management LLC decreased its holdings in ICU Medical, Inc. (NASDAQ:ICUI) by 18.2% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 140,909 shares of the medical instruments supplier’s stock after selling 31,272 shares during the quarter. William Blair Investment Management LLC owned 0.56% of ICU Medical worth $22,617,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Allworth Financial LP purchased a new stake in shares of ICU Medical in the second quarter valued at about $26,000. Versant Capital Management Inc boosted its holdings in ICU Medical by 26.2% during the third quarter. Versant Capital Management Inc now owns 313 shares of the medical instruments supplier’s stock worth $50,000 after purchasing an additional 65 shares during the last quarter. Public Employees Retirement System of Ohio bought a new stake in ICU Medical in the 2nd quarter worth about $51,000. Nykredit A S bought a new stake in ICU Medical in the 2nd quarter worth about $135,000. Finally, Vise Technologies Inc. purchased a new stake in ICU Medical in the 3rd quarter valued at about $227,000. Institutional investors and hedge funds own 96.10% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. Zacks Research cut shares of ICU Medical from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 28th. BTIG Research boosted their target price on ICU Medical from $170.00 to $200.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. KeyCorp upped their target price on ICU Medical from $187.00 to $189.00 and gave the company an “overweight” rating in a report on Friday, November 6th. Needham & Company LLC increased their price target on ICU Medical from $165.00 to $187.00 and gave the company a “buy” rating in a research report on Friday, August 7th. Finally, Raymond James Financial reiterated a “strong-buy” rating and set a $200.00 price target on shares of ICU Medical in a report on Friday, August 7th. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, ICU Medical presently has a consensus rating of “Moderate Buy” and a consensus price target of $195.20.

ICU Medical Stock Performance

ICUI traded up $1.97 during trading on Friday, hitting $179.27. 195,454 shares of the company traded hands, compared to its average volume of 278,884. The firm has a market cap of $4.48 billion, a P/E ratio of 75.01, a price-to-earnings-growth ratio of 2.23 and a beta of 0.88. The stock’s fifty day moving average is $163.72 and its 200 day moving average is $149.91. The company has a quick ratio of 1.19, a current ratio of 2.37 and a debt-to-equity ratio of 0.52. ICU Medical, Inc. has a one year low of $113.37 and a one year high of $192.85.

ICU Medical (NASDAQ:ICUI) last posted its quarterly earnings data on Thursday, November 5th. The medical instruments supplier reported $2.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.14 by $0.30. The business had revenue of $556.22 million during the quarter, compared to the consensus estimate of $552.03 million. ICU Medical had a net margin of 2.76% and a return on equity of 8.40%. The firm’s quarterly revenue was up 4.4% compared to the same quarter last year. During the same quarter last year, the company posted $2.03 earnings per share. As a group, equities analysts predict that ICU Medical, Inc. will post 7.22 EPS for the current fiscal year.

Insider Buying and Selling

In other news, VP Virginia Sanzone sold 4,856 shares of the firm’s stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $168.69, for a total transaction of $819,158.64. Following the completion of the sale, the vice president owned 14,604 shares in the company, valued at $2,463,548.76. This trade represents a 24.95% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Elisha Finney sold 1,700 shares of ICU Medical stock in a transaction that occurred on Friday, November 13th. The stock was sold at an average price of $179.00, for a total transaction of $304,300.00. Following the completion of the sale, the director directly owned 4,871 shares in the company, valued at $871,909. This trade represents a 25.87% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 6,621 shares of company stock valued at $1,135,094 over the last three months. Insiders own 2.10% of the company’s stock.

ICU Medical Profile

ICU Medical is a medical technology company that develops, manufactures and markets products used in infusion therapy, vascular access and critical care. Its offerings include infusion pumps and related sets and accessories, IV solutions, needlefree connectors, and products designed to help protect healthcare workers when handling hazardous drugs. Founded in 1984, the company expanded its product portfolio through acquisitions, including the infusion systems business of Hospira in 2017 and Smiths Medical in 2022.